Novo Nordisk A/S Stock SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT
Equities
NOVOB
DK0060102614
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- DKK | - |
|
01:48pm | Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation | MT |
10:56am | European shares slide as tech stocks weigh | RE |
Sales 2024 * | 292B 42.75B 58.4B | Sales 2025 * | 353B 51.75B 70.68B | Capitalization | 4,302B 631B 862B |
---|---|---|---|---|---|
Net income 2024 * | 103B 15.13B 20.66B | Net income 2025 * | 128B 18.79B 25.66B | EV / Sales 2024 * | 14.8 x |
Net Debt 2024 * | 21.69B 3.18B 4.34B | Net cash position 2025 * | 4.33B 635M 867M | EV / Sales 2025 * | 12.2 x |
P/E ratio 2024 * |
42.2
x | P/E ratio 2025 * |
33.7
x | Employees | - |
Yield 2024 * |
1.21% | Yield 2025 * |
1.5% | Free-Float | 70.3% |
Latest transcript on Novo Nordisk A/S
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 90-12-31 | |
Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
1st Jan change | Capi. | |
---|---|---|
+56.78% | 848B | |
-0.36% | 363B | |
+15.50% | 318B | |
+12.33% | 299B | |
+14.96% | 243B | |
+16.98% | 225B | |
+16.39% | 179B | |
+4.52% | 167B | |
+2.66% | 125B |
- Stock Market
- Equities
- NOVO B Stock
- NOVOB Stock